From the Editor

Value-based cancer care and the patient perspective


 

The business of cancer care is in transition. Driven by the Centers for Medicare & Medicaid Services’ (CMS) Oncology Care Model (OCM) program, practices around the country are working to re-engineer the way they provide services, and the way they charge for those services. The implicit goal of all this is to manage (as in reduce) the overall cost of cancer care. A more frequently stated goal is to improve value, typically defined as outcome (numerator) relative to cost (denominator). Alternative payment models are challenged to assess the value of transformational improvement in cancer care.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Growth in hospital-employed physicians shows no signs of slowing
MDedge Hematology and Oncology
Doctors have at least seven APM options in 2017
MDedge Hematology and Oncology
Drug prices, not the health law, top voters’ health priorities for 2017
MDedge Hematology and Oncology
7 tips for successful value-based care contracts
MDedge Hematology and Oncology
Number of Medicare part D drug plans continues to decline
MDedge Hematology and Oncology
Employer-provided insurance stable after ACA implementation
MDedge Hematology and Oncology
Meaningful use: CMS extends 90-day reporting period to 2016, 2017
MDedge Hematology and Oncology
What will the Trump administration mean for medicine?
MDedge Hematology and Oncology
NCCN: Deliver vincristine by mini IV drip bag
MDedge Hematology and Oncology
How to Tweet: a guide for physicians
MDedge Hematology and Oncology